BRPI0412059A - método para a preparação de formulação de liberação controlada - Google Patents

método para a preparação de formulação de liberação controlada

Info

Publication number
BRPI0412059A
BRPI0412059A BRPI0412059-0A BRPI0412059A BRPI0412059A BR PI0412059 A BRPI0412059 A BR PI0412059A BR PI0412059 A BRPI0412059 A BR PI0412059A BR PI0412059 A BRPI0412059 A BR PI0412059A
Authority
BR
Brazil
Prior art keywords
controlled release
release compositions
bioactive agent
present
production
Prior art date
Application number
BRPI0412059-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Gary P Cook
Original Assignee
Pr Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pr Pharmaceuticals Inc filed Critical Pr Pharmaceuticals Inc
Publication of BRPI0412059A publication Critical patent/BRPI0412059A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0412059-0A 2003-07-15 2004-07-15 método para a preparação de formulação de liberação controlada BRPI0412059A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48766303P 2003-07-15 2003-07-15
PCT/US2004/022816 WO2005009356A2 (en) 2003-07-15 2004-07-15 Method for the preparation of controlled release formulations

Publications (1)

Publication Number Publication Date
BRPI0412059A true BRPI0412059A (pt) 2006-09-05

Family

ID=34102710

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412059-0A BRPI0412059A (pt) 2003-07-15 2004-07-15 método para a preparação de formulação de liberação controlada

Country Status (9)

Country Link
US (1) US8871269B2 (cg-RX-API-DMAC7.html)
EP (2) EP1651136B1 (cg-RX-API-DMAC7.html)
JP (2) JP5165239B2 (cg-RX-API-DMAC7.html)
CN (2) CN1852687B (cg-RX-API-DMAC7.html)
AU (1) AU2004259208B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0412059A (cg-RX-API-DMAC7.html)
CA (1) CA2532302C (cg-RX-API-DMAC7.html)
ES (1) ES2625343T3 (cg-RX-API-DMAC7.html)
WO (1) WO2005009356A2 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2427092T3 (es) 2003-04-10 2013-10-28 Evonik Corporation Un método para la producción de micropartículas a base de emulsión
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
WO2005009356A2 (en) 2003-07-15 2005-02-03 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
EP1660039B1 (en) * 2003-07-18 2016-09-28 Oakwood Laboratories L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
EP2444069B1 (en) * 2003-07-23 2019-06-05 Evonik Corporation Controlled release compositions
AU2004313245B2 (en) * 2003-12-30 2011-04-14 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
US20100290982A1 (en) * 2007-04-13 2010-11-18 University Of North Texas Health Science Center At Fort Worth Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles
MX2009010907A (es) * 2007-04-13 2010-03-17 Univ North Texas Formulacion del agente activo cargado en nanoparticulas de plga activadas para nano-terapeuticos direccionados para el cancer.
EP2139458A4 (en) * 2007-04-19 2013-01-23 Dong A Pharm Co Ltd COMPOSITION OF BIODEGRADABLE MICROSPHERES WITH CONTROLLED RELEASE OF A GLUCOSE REGULATING PEPTIDE AND RELATED FORMULA
GB0709322D0 (en) * 2007-05-15 2007-06-20 Nordic Bioscience As Exposure agent for detection of vitamin d
WO2008145183A1 (en) * 2007-05-30 2008-12-04 Nestec S.A. Oil-in-water emulsion and its use for the delayed release of active elements
AU2008310956B2 (en) 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
ES2324009B1 (es) * 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
CA2714514C (en) * 2008-02-08 2016-08-16 Qps Llc Non-polymeric compositions for controlled drug delivery
US20100015240A1 (en) 2008-07-16 2010-01-21 Danielle Biggs Process for preparing microparticles containing bioactive peptides
AU2010259184B2 (en) 2009-06-09 2015-08-13 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
CA2770149A1 (en) * 2009-08-05 2011-02-10 Pieris Ag Controlled release formulations of lipocalin muteins
US20110151028A1 (en) * 2009-12-19 2011-06-23 Filiberto Zadini Topical vaginal preparation
ES2362604B1 (es) * 2009-12-22 2012-06-28 Bcn Peptides, S.A. Formulación tópica oftálmica de péptidos.
KR101913102B1 (ko) * 2010-03-11 2018-10-31 와이어쓰 엘엘씨 메틸날트렉손의 경구 제형 및 친유성 염
JP5222917B2 (ja) * 2010-09-21 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
TWI501781B (zh) * 2010-12-10 2015-10-01 Ind Tech Res Inst 可控制釋放的組合物及其製造方法
US20160151511A1 (en) * 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190117573A1 (en) * 2017-10-19 2019-04-25 Hyalo Technologies, LLC Composition and method of preparation of risperidone extended release preparation
US20230062487A1 (en) * 2020-01-24 2023-03-02 W. L. Gore & Associates, Inc. Sustained-release matrices for adventitial or periadventitial neural ablation and uses thereof
CN111643483B (zh) * 2020-07-06 2022-03-29 济南大学 一种用于制备加兰他敏缓释微球的方法
US11992559B2 (en) 2021-02-24 2024-05-28 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
EP4326237A4 (en) * 2021-04-23 2025-02-26 Flow Pharma Inc. Microsphere formulations comprising multiple non-identical peptides and methods for making the same
WO2023102018A1 (en) * 2021-12-02 2023-06-08 University Of Connecticut Long-acting injectable in situ forming biodegradable implants comprising non-steroidal anti-inflammatory drugs
CN116421578A (zh) * 2023-03-31 2023-07-14 辉粒药业(苏州)有限公司 生长抑素类似物缓释微球及其制备方法
AU2024253395A1 (en) * 2023-04-03 2025-10-02 Ferring B.V. Methods of manufacturing peptide salts

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3664963A (en) 1969-10-22 1972-05-23 Balchem Corp Encapsulation process
US3780195A (en) 1969-10-22 1973-12-18 Balchem Corp Encapsulation process
DE2059494B2 (de) 1970-12-03 1972-03-16 Licentia Gmbh Biegsamer hohlleiter
JPS523342B2 (cg-RX-API-DMAC7.html) 1972-01-26 1977-01-27
US3865352A (en) 1973-11-16 1975-02-11 Minnesota Mining & Mfg Static mixing device
DE2604832A1 (de) 1976-02-07 1977-08-11 Basf Ag Verfahren zur analyse von loesungen
US4171981A (en) 1977-04-29 1979-10-23 The Mead Corporation Process for the production of hot melt coating compositions containing microcapsules
US4183681A (en) 1978-05-19 1980-01-15 Exxon Research & Engineering Co. Emulsion preparation method using a packed tube emulsifier
US4299501A (en) 1979-08-10 1981-11-10 Ortho Pharmaceutical Corporation Continuous process for the preparation of semisolid dispersions
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4933105A (en) 1980-06-13 1990-06-12 Sandoz Pharm. Corp. Process for preparation of microspheres
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
DE3732370A1 (de) 1987-09-25 1989-04-06 Hoechst Ag Verfahren zur vermischung von lebenden zellen oder mikroorganismen mit einer viskosen fluessigkeit und mischungen, die nach diesem verfahren hergestellt wurden
DE69024953T3 (de) 1989-05-04 2005-01-27 Southern Research Institute, Birmingham Einkapselungsverfahren
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
FR2660556B1 (fr) * 1990-04-06 1994-09-16 Rhone Poulenc Sante Microspheres, leur procede de preparation et leur utilisation.
US6120805A (en) * 1990-04-06 2000-09-19 Rhone-Poulenc Rorer Sa Microspheres, process for their preparation and their use
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
NZ260909A (en) 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
EP1649850A1 (en) 1993-11-19 2006-04-26 Alkermes Controlled Therapeutics Inc. II Preparation of biodegradable microparticles containing a biologically active agent
JP2832143B2 (ja) 1993-12-28 1998-12-02 信越化学工業株式会社 シリコーン微粒子およびその製造方法
WO1997004747A1 (en) 1995-07-27 1997-02-13 Dunn James M Drug delivery systems for macromolecular drugs
US5629277A (en) * 1995-10-04 1997-05-13 William L. Brown Paint removing composition
US6140040A (en) 1995-10-06 2000-10-31 Advanced Minerals Corporation Method of mechanically separating microparticles suspended in fluids using particulate media
EP0799616A1 (en) 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
JPH10273447A (ja) 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
SE9701161D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
AR012448A1 (es) 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
JP4918188B2 (ja) 1997-12-16 2012-04-18 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド サブミクロンの水中油型エマルジョンと合わせた微粒子の使用
SK10272000A3 (sk) 1998-01-16 2001-01-18 Takeda Chemical Industries, Ltd. Prostriedok s trvalým uvoľňovaním, spôsob jeho výroby a jeho použitia
US6270700B1 (en) * 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides
JP3012608B1 (ja) 1998-09-17 2000-02-28 農林水産省食品総合研究所長 マイクロチャネル装置及び同装置を用いたエマルションの製造方法
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
EP1044683A1 (en) * 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
AU7853500A (en) 1999-10-08 2001-04-23 Procter & Gamble Company, The Apparatus and process for in-line preparation of hipes
AUPQ529000A0 (en) * 2000-01-28 2000-02-17 Research Laboratories Of Australia Pty Ltd Toner characterization cell
US6953593B2 (en) 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
JP2002126043A (ja) * 2000-07-17 2002-05-08 Takeda Chem Ind Ltd 凍結乾燥物の製造法
US6565873B1 (en) 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
WO2002036169A2 (en) * 2000-10-31 2002-05-10 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
JP2004525403A (ja) 2001-01-15 2004-08-19 スリーエム イノベイティブ プロパティズ カンパニー 可視波長領域における透過が高く、かつ平滑な多層赤外反射フィルム、およびそれから製造される積層物品
CA2435415A1 (en) 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticles of biodegradable polymer encapsulating a biologically active substance
AR034641A1 (es) * 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla
US20060083778A1 (en) 2002-05-03 2006-04-20 Dean Allison Controlled release compositions of estradiol metabolites
JP2007525442A (ja) * 2003-03-05 2007-09-06 ピーアール ファーマシューティカルズ，インコーポレイテッド オキシトシン制御放出処方物およびオキシトシン制御放出処方物を使用する方法
ES2427092T3 (es) 2003-04-10 2013-10-28 Evonik Corporation Un método para la producción de micropartículas a base de emulsión
US20070207211A1 (en) 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
BRPI0409322B8 (pt) 2003-04-11 2021-05-25 Antriabio Inc método para preparar um conjugado de insulina-polímero
WO2005009356A2 (en) 2003-07-15 2005-02-03 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
EP2444069B1 (en) 2003-07-23 2019-06-05 Evonik Corporation Controlled release compositions

Also Published As

Publication number Publication date
US8871269B2 (en) 2014-10-28
EP1651136B1 (en) 2017-03-08
EP2462896A1 (en) 2012-06-13
US20060228414A1 (en) 2006-10-12
EP1651136A2 (en) 2006-05-03
JP2011144207A (ja) 2011-07-28
CN1852687A (zh) 2006-10-25
JP5165239B2 (ja) 2013-03-21
CN102935069A (zh) 2013-02-20
WO2005009356A2 (en) 2005-02-03
AU2004259208A1 (en) 2005-02-03
CN1852687B (zh) 2014-01-22
WO2005009356A3 (en) 2005-06-09
CA2532302A1 (en) 2005-02-03
ES2625343T3 (es) 2017-07-19
JP2007524645A (ja) 2007-08-30
EP1651136A4 (en) 2009-07-08
CA2532302C (en) 2016-12-20
AU2004259208B2 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
BRPI0412059A (pt) método para a preparação de formulação de liberação controlada
ES2178268T3 (es) Formulaciones de liberacion controlada.
AR063471A1 (es) Formulaciones para administracion parenteral de compuestos y sus usos
BRPI0913326C1 (pt) formulação farmacêuticas tópicas contendo uma baixa concentração de peróxido de benzoíla em suspensão aquosa e um solvente orgânico miscível em água
BRPI0507473A (pt) cápsula de gelatina mole, uso de pelo menos um ácido graxo polinsaturado Èmega-3, processo para a manufatura de uma cápsula de gelatina mole, uso de gelatina extraìda por um processo de extração, e, método de tratamento ou de profilaxia de uma condição
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
PE20080765A1 (es) Formas de dosificacion farmaceutica
BRPI0509062A (pt) composição para preparação farmacêutica sólida de solifenacina ou seu sal
SV2002000250A (es) Formula de dosis de droga accionada por hidrogel ref. pc10818ajtb/bb
BR112014004460A2 (pt) material polimérico para um recipiente isolado
BRPI0406905A (pt) Espuma de fosfato de clindamicina
BRPI0309142B8 (pt) suspensão de microcápsulas em uma fase líquida aquosa, que permite a liberação modificada de pelo menos um princípio ativo com exclusão da amoxicilina e que é destinada a ser administrada por via oral
BRPI0508933A (pt) composições para entrega tópica
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
BRPI0822162B8 (pt) composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
BRPI0014869B8 (pt) prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
AR060063A1 (es) Material cementicio, formulacion de material cementicio y articulo obtenido
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
BR112022026699A2 (pt) Mecanismo de liberação de fragrâncias, método e usos do mesmo
BRPI0412063A (pt) um método para produzir ácido orgánico
AR027748A1 (es) Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma
JP2017514924A5 (cg-RX-API-DMAC7.html)
BR112015026053A8 (pt) composição farmacêutica, recipiente vedado, inalador dosimetrado, uso de um componente propelente, e, método para fabricação de uma composição farmacêutica
BRPI0606393A2 (pt) prevenção de doenças trombóticas com compostos ativos de vitamina d ou similares do mesmo

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.